- SPANNR
- Posts
- Issue #48
Issue #48
Issue #48
April 27, 2023 | Issue #48
Good afternoon. Welcome back to another issue of Spannr.In this week's newsletter:💤 The great sleep debate👁️ From mice to monkeys: Life Bio’s breakthrough💸 This week in funding🌐 Good reads from around the web
Sleep Quality vs. Quantity: Which is Most Important?
During a recent visit to a local gym, we came across a new member, disheartened by her persistent inability to lose weight despite conscientious efforts. She carefully managed her diet and exercised six days a week, but nothing seemed to work. Calories in, calories out,
right?
Pondering her situation, a former colleague inquired, "How many hours of sleep do you get a night?"
"Four."
In a moment of inspiration, he proposed a simple experiment: "Let's keep your diet and exercise routine the same. We won't alter your meals or add more workouts. I just want you to get one more hour of sleep a night. Just one."
The new member complied, and within a week, she returned to the gym, thrilled to share a five-pound weight loss – all from adding merely an extra hour of sleep each night.
This revelation underscored the immense impact sleep has on our well-being and reinforced its crucial role in maintaining overall health. Yet, even with such awareness, many continue to grapple with making sleep a priority.
In
, we dive into the significance of sleep quality and quantity for fostering a longer, healthier life, and attempt to address the pervasive question –
which holds more weight
?
Ultimately, we reveal practical and evidence-based approaches to refine sleep habits and bolster one's longevity.
Life Biosciences presents groundbreaking data at ARVO
Life Biosciences has achieved a breakthrough by successfully improving vision in nonhuman primates using a gene therapy candidate based on partial epigenetic reprogramming.
In layman's terms, this is a huge leap for the field of longevity, as it demonstrates that the technique, which has previously only been proven to turn back the clock and enhance vision in
mice
, can also work in
primates
.
The
, with results presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Conference earlier this week, targeted a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which causes sudden vision loss similar to a stroke in the eye.
Life Biosciences' therapy employed a combination of three Yamanaka factors (Oct4, Sox2, and Klf4, or
), to help rejuvenate cells and restore vision in the primates. This promising outcome increases the likelihood of future human clinical trials.
Dr. David Sinclair, a leading expert in the field and co-founder of Life Biosciences, highlights the significance of this achievement.
While Sinclair is known for his optimism and is sometimes accused of overhyping longevity developments, we must give credit where it's due.
The success of this therapy has major implications for Life Biosciences and the entire longevity industry, potentially opening up new research paths and treatments for various eye disorders and other age-related diseases.
Cortical Labs raised $10 million for its Pong-playing stem cells that eventually could power AI. The round was led by Horizons Ventures, with participation from LifeX Ventures (the launch of which we covered last year), Blackbird Ventures, Radar Ventures, and In-Q-Tel
SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the diseases of ageing, today announces that it has been awarded a £571,350 grant from Innovate UK, the UK’s innovation agency, towards the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF)
The "Stepping Stone" Approach to Getting Longevity Drugs To Market (Proto.life)
'It totally backfired': The pitfalls of Alzheimer's genetic testing (Reuters)
Mitochondria Power-Supply Failure May Cause Age-Related Cognitive Impairment (Salk)
The Quest for Longevity Is Already Over (Wired)
What Was the Life Expectancy of Ancient Humans? (Discover Magazine)
A Silent Crisis in Men’s Health Gets Worse (Washington Post)
Longevity: The Retirement Problem No One Is Discussing (Kiplinger)
Humans can't live forever, but we haven't even come close to the limit for how long our bodies could last (Inside)
Performance:
Latest Price: $98.907d-Return: 5.40%Market Cap: $10.11b
ABOUT SPANNR
We are dedicated to helping people understand the biggest business and health story of all time: the unprecedented transformation of society that will result from extending human healthspan and lifespan.
If you have any questions about Spannr or want to get to know us better,
– we'd love to hear from you. We appreciate your interest in what we are creating.